Advancing SarcomaResearch
Rein in Sarcoma supports innovative research that strengthens the understanding, diagnosis, and treatment of sarcoma. Our current projects represent meaningful collaborations with leading institutions and investigators who are committed to improving care for patients.
Featured Projects
Our current portfolio includes projects focused on:
- Novel Therapeutics: Investigating new treatment strategies and drug development.
- Early Detection: Research into biomarkers and diagnostic pathways to shorten time to diagnosis.
- Patient Outcomes: Studies designed to improve quality of life and survivorship.
Research Summaries
We provide transparent updates on the projects currently supported by Rein In Sarcoma, including objectives, methodologies, and progress.
• Institutional Collaborations: Partnerships with top sarcoma research centers.
• Grant Recipients: Profiles of investigators leading cutting-edge studies.
• Progress Reports: Updates on milestones and published findings.
Research News
Stay informed with the latest publications, conference presentations, and updates from our funded projects. Rein In Sarcoma connects medical professionals with the broader sarcoma research community.
Partnering For Discovery
Rein in Sarcoma invites medical professionals to join us in advancing the research that shapes the future of sarcoma care. By engaging with our funded studies and collaborating with leading investigators, we can accelerate new discoveries and improve treatment options for patients and families.
RIS-Funded Research Project Publishes First Findings
In May 2024, Rein in Sarcoma (RIS) awarded a research grant to the University of Calgary through the Kasey Altman Research Fund. Just one year later, the project has already reached an exciting milestone: the research team has published its initial findings in Scientific Reports, a journal within the Nature family.
About the Project
The study focuses on rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children. Researchers are looking closely at how certain cells in the tumor’s environment, called cancer-associated fibroblasts, may help the cancer grow or resist treatment. By understanding these interactions, the team hopes to uncover new opportunities to weaken the tumor and improve outcomes for patients.
Why This Matters
This early publication shows strong progress and highlights the impact of RIS-funded research. The University of Calgary team reports that the project is well underway, with promising results guiding the next phase of their work.
Your Support at Work
This milestone reinforces the vital role of donor-supported research at Rein in Sarcoma. By investing in cutting-edge scientific work with the potential for real clinical impact. We are proud to see meaningful advances happening so quickly as RIS continues its mission to drive progress toward better treatments and, ultimately, a cure for sarcoma cancers.
The published article can be accessed here: “Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma | Scientific Reports”, for those interested in exploring the full findings.